Our Latest News - BUHLMANN

BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics

BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics.

LabSense News Q3 2020 Edition

In this “Q3 2020 Edition” we introduce two NEW BUHLMANN Products. The new FDA Exempt, fecal Pancreatic Elastase (fPELA®) turbo assay, as well newly developed Quantum Blue® 3 Reader (QB3). Also watch the IBDoc® video ‘Want to improve care for IBD patients?’ and lastly watch Dr. Arne Roseth’s AMLI presentation “The latest on IBD Care

Educational Webinar recording from AMLI presentation by Dr Arne Roseth

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important

BÜHLMANN anti-MAG autoantibodies ELISA Citations

US: BÜHLMANN GanglioCombi™ ELISA is for Research Use Only. Not for use in diagnostic procedures. Health Canada Licence: 100436 and 100476 The citation list should be used for information only. Van den Bergh, P.Y.K., et al., 2021: European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of

BÜHLMANN anti-SGPG autoantibodies ELISA Citations

US: BÜHLMANN GanglioCombi™ ELISA is for Research Use Only. Not for use in diagnostic procedures. Health Canada Licence: 100436 and 100476 The citation list should be used for information only. Herrendorff R et , 2017: Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen specific treatment option for anti-MAG neuropathy. PNAS, www.pnas.org/cgi/doi/10.1073/pnas.1619386114 DOI: 10.1073/pnas.1619386114

BÜHLMANN anti Ganglioside antibodies Citations

US: BÜHLMANN GanglioCombi™ ELISA is for Research Use Only. Not for use in diagnostic procedures. Health Canada Licence: 100436 and 100476 The citation list should be used for information only. Toscano G et al., 2020; Guillain-Barré Syndrome Associated with SARS-CoV-2 (Letter to the editor); NEJM; April 27, 2020 DOI: 10.1056/NEJMc2009191 Continue Reading Delmont E et

External Quality Assessment Scheme for Basophil Activation Test

We are pleased to inform you that the first External Quality Assessment (EQA) Scheme for Basophil Activation Test (BAT) is now available.

Use of basophil activation in oral immunotherapy

An outstanding research paper was published in the top rated Journal of Allergen and Clinical Immunology which evaluated the performance of basophil activation as a biomarker in monitoring clinical efficacy of oral peanut immunotherapy in a clinical trial.

CALEX Cap Promotion

BÜHLMANN fCAL® turbo + CALEX® Cap (K191718): FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 98839 CALEX® Cap CALEX® Cap is an FDA 510(k) cleared fecal extraction device for use with BÜHLMANN fCAL® turbo that provides excellent correlation to the traditional manual weighing method and offers efficient, convenient and hygienic extraction of stool samples. Its unique design

Protected: Historical Overview of Ganglioside Antibodies

There is no excerpt because this is a protected post.

BUHLMANN News

BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics

LabSense News Q3 2020 Edition

Educational Webinar recording from AMLI presentation by Dr Arne Roseth

BÜHLMANN anti-MAG autoantibodies ELISA Citations

BÜHLMANN anti-SGPG autoantibodies ELISA Citations

BÜHLMANN anti Ganglioside antibodies Citations

External Quality Assessment Scheme for Basophil Activation Test

Use of basophil activation in oral immunotherapy

CALEX Cap Promotion

Protected: Historical Overview of Ganglioside Antibodies

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US